Top

Published in:

01-05-2020 | Breast Cancer | Original Article

Co-expression of HLA-I loci improved prognostication in HER2+ breast cancers

Authors: Julia Y. Tsang, Chun-Sing Ho, Yun-Bi Ni, Yan Shao, Ivan K. Poon, Siu-Ki Chan, Sai-Yin Cheung, Ka-Ho Shea, Monalyn Marabi, Gary M. Tse

Published in: Cancer Immunology, Immunotherapy | Issue 5/2020

Abstract

The underlying basis for cancer immune evasion is important for effective immunotherapy and prognosis in breast cancers. Human leucocyte antigens (HLA)-I comprising three classical antigens (HLA-A, -B and -C) is mandatory for anti-tumor immunity. Its loss occurred frequently in many cancers resulting in effective immune evasion. Most studies examined HLA-I as a whole. Alterations in specific locus could have different clinical ramifications. Hence, we evaluated the expression of the three HLA-I loci in a large cohort of breast cancers. Low expression of HLA-A, -B and -C were found in 71.1%, 66.3%, and 60.2% of the cases. Low and high expression in all loci was found in 48.3% and 17.9% of the cases respectively. The remaining showed high expression in one or two loci. Cases with all HLA high expression (all HLA high) was frequent in the ER-HER2- (27.4%) and ER-HER2+ (23.1%) cases and was associated with characteristic pathologic features related to these tumor (higher grade, necrosis, high tumor infiltrating lymphocyte (TIL), pT stage, low hormonal receptor, high basal marker expression) (p ≤ 0.019). Interestingly, in HER2+ cancers, only cases with all HLA high and high TIL showed significantly better survival. In node positive cancers, concordant high HLA expression in primary tumors and nodal metastases was favorable prognostically (DFS: HR = 0.741, p < 0.001; BCSS: HR = 0.699, p = 0.003). The data suggested an important clinical value of a combined analysis on the co-expression HLA-I status in both primary and metastatic tumors. This could be a potential additional key component to be incorporated into TIL evaluation for improved prognostication.

Available only for authorised users

Ghahremanloo A, Soltani A, Modaresi SMS, Hashemy SI (2019) Recent advances in the clinical development of immune checkpoint blockade therapy. Cell Oncol (Dordr). https://doi.org/10.1007/s13402-019-00456-w CrossRef

Atezolizumab Combo Approved for PD-L1-positive TNBC (2019). Cancer Discov 9 (5):OF2. 10.1158/2159–8290.CD-NB2019–038

Garrido F, Aptsiauri N, Doorduijn EM, Garcia Lora AM, van Hall T (2016) The urgent need to recover MHC class I in cancers for effective immunotherapy. Curr Opin Immunol 39:44–51. https://doi.org/10.1016/j.coi.2015.12.007 CrossRefPubMedPubMedCentral

Garrido F, Cabrera T, Aptsiauri N (2010) "Hard" and "soft" lesions underlying the HLA class I alterations in cancer cells: implications for immunotherapy. Int J Cancer 127(2):249–256. https://doi.org/10.1002/ijc.25270 CrossRefPubMed

de Kruijf EM, van Nes JG, Sajet A, Tummers QR, Putter H, Osanto S, Speetjens FM, Smit VT, Liefers GJ, van de Velde CJ, Kuppen PJ (2010) The predictive value of HLA class I tumor cell expression and presence of intratumoral Tregs for chemotherapy in patients with early breast cancer. Clin Cancer Res 16(4):1272–1280. https://doi.org/10.1158/1078-0432.CCR-09-1844 CrossRefPubMed

Gudmundsdottir I, Gunnlaugur Jonasson J, Sigurdsson H, Olafsdottir K, Tryggvadottir L, Ogmundsdottir HM (2000) Altered expression of HLA class I antigens in breast cancer: association with prognosis. Int J Cancer 89(6):500–505CrossRefPubMed

Kaneko K, Ishigami S, Kijima Y, Funasako Y, Hirata M, Okumura H, Shinchi H, Koriyama C, Ueno S, Yoshinaka H, Natsugoe S (2011) Clinical implication of HLA class I expression in breast cancer. BMC Cancer 11:454. https://doi.org/10.1186/1471-2407-11-454 CrossRefPubMedPubMedCentral

Park HS, Cho U, Im SY, Yoo CY, Jung JH, Suh YJ, Choi HJ (2019) Loss of human leukocyte antigen class I expression is associated with poor prognosis in patients with advanced breast cancer. J Pathol Transl Med 53(2):75–85. https://doi.org/10.4132/jptm.2018.10.11 CrossRefPubMed

Lee HJ, Song IH, Park IA, Heo SH, Kim YA, Ahn JH, Gong G (2016) Differential expression of major histocompatibility complex class I in subtypes of breast cancer is associated with estrogen receptor and interferon signaling. Oncotarget 7(21):30119–30132. https://doi.org/10.18632/oncotarget.8798 CrossRefPubMedPubMedCentral

10.

Garrido MA, Rodriguez T, Zinchenko S, Maleno I, Ruiz-Cabello F, Concha A, Olea N, Garrido F, Aptsiauri N (2018) HLA class I alterations in breast carcinoma are associated with a high frequency of the loss of heterozygosity at chromosomes 6 and 15. Immunogenetics 70(10):647–659. https://doi.org/10.1007/s00251-018-1074-2 CrossRefPubMed

11.

Madjd Z, Spendlove I, Pinder SE, Ellis IO, Durrant LG (2005) Total loss of MHC class I is an independent indicator of good prognosis in breast cancer. Int J Cancer 117(2):248–255. https://doi.org/10.1002/ijc.21163 CrossRefPubMed

12.

Torigoe T, Asanuma H, Nakazawa E, Tamura Y, Hirohashi Y, Yamamoto E, Kanaseki T, Hasegawa T, Sato N (2012) Establishment of a monoclonal anti-pan HLA class I antibody suitable for immunostaining of formalin-fixed tissue: unusually high frequency of down-regulation in breast cancer tissues. Pathol Int 62(5):303–308. https://doi.org/10.1111/j.1440-1827.2012.02789.x CrossRefPubMed

13.

Vertuani S, Triulzi C, Roos AK, Charo J, Norell H, Lemonnier F, Pisa P, Seliger B, Kiessling R (2009) HER-2/neu mediated down-regulation of MHC class I antigen processing prevents CTL-mediated tumor recognition upon DNA vaccination in HLA-A2 transgenic mice. Cancer Immunol Immunother 58(5):653–664. https://doi.org/10.1007/s00262-008-0587-1 CrossRefPubMed

14.

Benevolo M, Mottolese M, Piperno G, Sperduti I, Cione A, Sibilio L, Martayan A, Donnorso RP, Cosimelli M, Giacomini P (2007) HLA-A, -B, -C expression in colon carcinoma mimics that of the normal colonic mucosa and is prognostically relevant. Am J Surg Pathol 31(1):76–84. https://doi.org/10.1097/01.pas.0000213343.55605.b9 CrossRefPubMed

15.

de Jong RA, Boerma A, Boezen HM, Mourits MJ, Hollema H, Nijman HW (2012) Loss of HLA class I and mismatch repair protein expression in sporadic endometrioid endometrial carcinomas. Int J Cancer 131(8):1828–1836. https://doi.org/10.1002/ijc.27449 CrossRefPubMed

16.

Tsang JY, Au WL, Lo KY, Ni YB, Hlaing T, Hu J, Chan SK, Chan KF, Cheung SY, Tse GM (2017) PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients. Breast Cancer Res Treat 162(1):19–30. https://doi.org/10.1007/s10549-016-4095-2 CrossRefPubMed

17.

Goodman ML, Trinca GM, Walter KR, Papachristou EK, D'Santos CS, Li T, Liu Q, Lai Z, Chalise P, Madan R, Fan F, Markiewicz MA, Jin VX, Carroll JS, Hagan CR (2019) Progesterone receptor attenuates STAT1-mediated IFN signaling in breast cancer. J Immunol 202(10):3076–3086. https://doi.org/10.4049/jimmunol.1801152 CrossRefPubMed

18.

Choudhury A, Charo J, Parapuram SK, Hunt RC, Hunt DM, Seliger B, Kiessling R (2004) Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines. Int J Cancer 108(1):71–77. https://doi.org/10.1002/ijc.11497 CrossRefPubMed

19.

Inoue M, Mimura K, Izawa S, Shiraishi K, Inoue A, Shiba S, Watanabe M, Maruyama T, Kawaguchi Y, Inoue S, Kawasaki T, Choudhury A, Katoh R, Fujii H, Kiessling R, Kono K (2012) Expression of MHC Class I on breast cancer cells correlates inversely with HER2 expression. Oncoimmunology 1(7):1104–1110. https://doi.org/10.4161/onci.21056 CrossRefPubMedPubMedCentral

20.

Li G, Xie Q, Yang Z, Wang L, Zhang X, Zuo B, Zhang S, Yang A, Jia L (2019) Sp1-mediated epigenetic dysregulation dictates HDAC inhibitor susceptibility of HER2-overexpressing breast cancer. Int J Cancer 145(12):3285–3298. https://doi.org/10.1002/ijc.32425 CrossRefPubMed

21.

Paul S, Weiskopf D, Angelo MA, Sidney J, Peters B, Sette A (2013) HLA class I alleles are associated with peptide-binding repertoires of different size, affinity, and immunogenicity. J Immunol 191(12):5831–5839. https://doi.org/10.4049/jimmunol.1302101 CrossRefPubMed

22.

Muntasell A, Rojo F, Servitja S, Rubio-Perez C, Cabo M, Tamborero D, Costa-Garcia M, Martinez-Garcia M, Menendez S, Vazquez I, Lluch A, Gonzalez-Perez A, Rovira A, Lopez-Botet M, Albanell J (2019) NK cell infiltrates and HLA class I expression in primary HER2(+) breast cancer predict and uncouple pathological response and disease-free survival. Clin Cancer Res 25(5):1535–1545. https://doi.org/10.1158/1078-0432.CCR-18-2365 CrossRefPubMed

23.

Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, Rouas G, Francis P, Crown JP, Hitre E, de Azambuja E, Quinaux E, Di Leo A, Michiels S, Piccart MJ, Sotiriou C (2013) Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02–98. J Clin Oncol 31(7):860–867. https://doi.org/10.1200/JCO.2011.41.0902 CrossRefPubMed

24.

Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D, Kellokumpu-Lehtinen PL, Bono P, Kataja V, Desmedt C, Piccart MJ, Loibl S, Denkert C, Smyth MJ, Joensuu H, Sotiriou C (2014) Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol 25(8):1544–1550. https://doi.org/10.1093/annonc/mdu112 CrossRefPubMed

25.

Perez EA, Ballman KV, Tenner KS, Thompson EA, Badve SS, Bailey H, Baehner FL (2016) Association of stromal tumor-infiltrating lymphocytes with recurrence-free survival in the N9831 adjuvant trial in patients with early-stage HER2-positive breast cancer. JAMA Oncol 2(1):56–64. https://doi.org/10.1001/jamaoncol.2015.3239 CrossRefPubMedPubMedCentral

26.

Pereira ER, Kedrin D, Seano G, Gautier O, Meijer EFJ, Jones D, Chin SM, Kitahara S, Bouta EM, Chang J, Beech E, Jeong HS, Carroll MC, Taghian AG, Padera TP (2018) Lymph node metastases can invade local blood vessels, exit the node, and colonize distant organs in mice. Science 359(6382):1403–1407. https://doi.org/10.1126/science.aal3622 CrossRefPubMedPubMedCentral

27.

Cordon-Cardo C, Fuks Z, Drobnjak M, Moreno C, Eisenbach L, Feldman M (1991) Expression of HLA-A, B, C antigens on primary and metastatic tumor cell populations of human carcinomas. Cancer Res 51(23 Pt 1):6372–6380PubMed

28.

Vitale M, Rezzani R, Rodella L, Zauli G, Grigolato P, Cadei M, Hicklin DJ, Ferrone S (1998) HLA class I antigen and transporter associated with antigen processing (TAP1 and TAP2) down-regulation in high-grade primary breast carcinoma lesions. Cancer Res 58(4):737–742PubMed

29.

Liu Y, Komohara Y, Domenick N, Ohno M, Ikeura M, Hamilton RL, Horbinski C, Wang X, Ferrone S, Okada H (2012) Expression of antigen processing and presenting molecules in brain metastasis of breast cancer. Cancer Immunol Immunother 61(6):789–801. https://doi.org/10.1007/s00262-011-1137-9 CrossRefPubMed

30.

Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, Torrejon DY, Abril-Rodriguez G, Sandoval S, Barthly L, Saco J, Homet Moreno B, Mezzadra R, Chmielowski B, Ruchalski K, Shintaku IP, Sanchez PJ, Puig-Saus C, Cherry G, Seja E, Kong X, Pang J, Berent-Maoz B, Comin-Anduix B, Graeber TG, Tumeh PC, Schumacher TN, Lo RS, Ribas A (2016) Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med 375(9):819–829. https://doi.org/10.1056/NEJMoa1604958 CrossRefPubMedPubMedCentral

31.

Chowell D, Morris LGT, Grigg CM, Weber JK, Samstein RM, Makarov V, Kuo F, Kendall SM, Requena D, Riaz N, Greenbaum B, Carroll J, Garon E, Hyman DM, Zehir A, Solit D, Berger M, Zhou R, Rizvi NA, Chan TA (2018) Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Science 359(6375):582–587. https://doi.org/10.1126/science.aao4572 CrossRefPubMed

32.

Chan TA, Yarchoan M, Jaffee E, Swanton C, Quezada SA, Stenzinger A, Peters S (2019) Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol 30(1):44–56. https://doi.org/10.1093/annonc/mdy495 CrossRefPubMed

33.

McGranahan N, Rosenthal R, Hiley CT, Rowan AJ, Watkins TBK, Wilson GA, Birkbak NJ, Veeriah S, Van Loo P, Herrero J, Swanton C, Consortium TR (2017) Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution. Cell 171 (6):1259–1271e1211. doi:10.1016/j.cell.2017.10.001.

34.

Kershaw MH, Devaud C, John LB, Westwood JA, Darcy PK (2013) Enhancing immunotherapy using chemotherapy and radiation to modify the tumor microenvironment. Oncoimmunology 2(9):e25962. https://doi.org/10.4161/onci.25962 CrossRefPubMedPubMedCentral

35.

Kwilas AR, Donahue RN, Bernstein MB, Hodge JW (2012) In the field: exploiting the untapped potential of immunogenic modulation by radiation in combination with immunotherapy for the treatment of cancer. Front Oncol 2:104. https://doi.org/10.3389/fonc.2012.00104 CrossRefPubMedPubMedCentral

36.

Voorwerk L, Slagter M, Horlings HM, Sikorska K, van de Vijver KK, de Maaker M, Nederlof I, Kluin RJC, Warren S, Ong S, Wiersma TG, Russell NS, Lalezari F, Schouten PC, Bakker NAM, Ketelaars SLC, Peters D, Lange CAH, van Werkhoven E, van Tinteren H, Mandjes IAM, Kemper I, Onderwater S, Chalabi M, Wilgenhof S, Haanen J, Salgado R, de Visser KE, Sonke GS, Wessels LFA, Linn SC, Schumacher TN, Blank CU, Kok M (2019) Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial. Nat Med 25(6):920–928. https://doi.org/10.1038/s41591-019-0432-4 CrossRefPubMed

Title: Co-expression of HLA-I loci improved prognostication in HER2+ breast cancers
Authors: Julia Y. Tsang
Chun-Sing Ho
Yun-Bi Ni
Yan Shao
Ivan K. Poon
Siu-Ki Chan
Sai-Yin Cheung
Ka-Ho Shea
Monalyn Marabi
Gary M. Tse
Publication date: 01-05-2020
Publisher: Springer Berlin Heidelberg
Keywords: Breast Cancer
Breast Cancer
Published in: Cancer Immunology, Immunotherapy / Issue 5/2020
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-020-02512-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2020

“Tumor immunology meets oncology (TIMO) XV”, April 25th–27th 2019, Halle/Saale, Germany

Tumor mutational load, CD8+ T cells, expression of PD-L1 and HLA class I to guide immunotherapy decisions in NSCLC patients

CD160 expression on CD8+ T cells is associated with active effector responses but limited activation potential in pancreatic cancer

LincRNA-p21 knockdown reversed tumor-associated macrophages function by promoting MDM2 to antagonize* p53 activation and alleviate breast cancer development

Activation of TLR4 signaling inhibits progression of osteosarcoma by stimulating CD8-positive cytotoxic lymphocytes

CIK cell cytotoxicity is a predictive biomarker for CIK cell immunotherapy in postoperative patients with hepatocellular carcinoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer